These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19959102)

  • 1. Is there a role for maintenance therapy in acute myeloid leukaemia?
    Baer MR
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):517-21. PubMed ID: 19959102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?
    Rowe JM
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):509-15. PubMed ID: 19959101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post remission therapy in acute myeloid leukaemia (AML): the Medical Research Council experience in the UK.
    Rees JK; Gray RG
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():70-1. PubMed ID: 2697405
    [No Abstract]   [Full Text] [Related]  

  • 7. [Modern strategies in therapy of acute myeloid leukemia (AML) in adulthood. I. Primary treatment of de novo AML].
    Jehn U; Dengler R; Petrides PE
    Internist (Berl); 1996 Jun; 37(6):661-8. PubMed ID: 8768003
    [No Abstract]   [Full Text] [Related]  

  • 8. [Recent progress in the treatment of acute leukemia].
    Kimura Y
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):895-901. PubMed ID: 12894700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of therapy of 100 patients with acute leukemia--a retrospective unicenter 5-year analysis].
    Kubel M; Helbig W; Schwenke H; Hoffmann FA; Leiblein S; Schulze E; Pönisch W; Krahl R; Zuleger B
    Z Gesamte Inn Med; 1989 Jan; 44(2):58-64. PubMed ID: 2650473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of autologous immunity to acute myeloid leukaemia and maintenance of complete remission following interferon-alpha treatment.
    Lowdell MW; Craston R; Prentice HG
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):119-21. PubMed ID: 10515684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapy of malignant systemic diseases: hemoblastoses and malignant lymphomas].
    Schmidt CG
    Arzneimittelforschung; 1987 Feb; 37(2A):279-87. PubMed ID: 3551972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukaemia (AML).
    Rees JK
    Biomed Pharmacother; 1987; 41(4):196. PubMed ID: 3476163
    [No Abstract]   [Full Text] [Related]  

  • 16. [Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
    Creutzig U; Zimmermann M; Reinhardt D; Lehrnbecher T
    Klin Padiatr; 2003; 215(3):151-8. PubMed ID: 12778355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in the treatment of acute myeloid leukemia in children. Experience of the Argentinian Group of Acute Leukemia Treatment and the Latin American Group of Malignant Hemopathies Treatment 1967-1987].
    Freigeiro D; Scaglione C; Santarelli MT; Sackmann Muriel F; Jiménez E; Pavlovsky S; Bustelo P; Richard L; Kohan R; Kvicala R
    Sangre (Barc); 1989 Jun; 34(3):221-8. PubMed ID: 2669186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consolidation therapy: what should be the standard of care?
    Rowe JM
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):53-60. PubMed ID: 18342812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of immunotherapy in acute myelogenous leukemia.
    Foon KA; Smalley RV; Riggs CW; Gale RP
    Arch Intern Med; 1983 Sep; 143(9):1726-31. PubMed ID: 6577818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quality of life and coping with illness in patients with acute myeloid leukemia].
    Schumacher A; Kessler T; Riedel A; Büchner T; van de Loo J
    Psychother Psychosom Med Psychol; 1996 Nov; 46(11):385-90. PubMed ID: 9036412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.